Media
This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room
ZOMETA® (zoledronic acid)
www.zometa.com
(For Non U.S. Health Care Professionals Only)
ZOMETA CONTACT
ZOMETA® is indicated for the prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone or tumour-induced hypercalcameia) in patients with advanced malignancies involving bone.
- Treatment of tumor-induced hypercalcemia
This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.
ZOMETA Press Releases
Zometa Images
-
07-Dec-2011
Zometa Product Shot
-
-
18-Nov-2011
Zometa Ready To Use Product Shot
-
Zometa Videos
Physician Sound Bites
ZOMETA Additional Materials
-
18-Nov-2011
AZURE Trial Design -
18-Nov-2011
Cancer: Its Effect on Bones Fact Sheet -
03-Jun-2011
ABCSG-12 Trial Design -
03-Jun-2011
Zometa Fact Sheet -
03-Jun-2011
Bone Metastases Backgrounder -
3-Jun-2011
Myeloma IX Trial Design -
01-Jan-2011
Breast Cancer Recurrence Backgrounder -
01-Jan-2011
Breast Cancer and Distant Recurrence Backgrounder
SEARCH OUR WEBSITES
ABOUT NOVARTIS ONCOLOGY
We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.
